Fapon Unveils Innovative AI-based Enzymes and Alzheimer's Diagnostics at ADLM 2026

Fapon, a prominent global provider in the in vitro diagnostics (IVD) sector, is set to showcase its latest innovations at the upcoming ADLM 2026, taking place from July 26-30 in Anaheim, California. This event marks a pivotal moment for Fapon as it solidifies its commitment to enhancing diagnostic solutions within North America. The company will present its cutting-edge AI-engineered enzymes designed for molecular diagnostics, as well as a complete range of blood-based reagents tailored for Alzheimer's disease diagnostics.

Highlights from Fapon's Showcase at Booth 3161

Attendees at ADLM 2026 can expect to explore Fapon's groundbreaking AI-engineered enzymes, ProPrime II and MeloScript III. These enzymes are engineered to significantly enhance the sensitivity, speed, and reliability of PCR and qPCR workflows, essential for accurate molecular diagnostics. Fapon assures attendees of its full freedom-to-operate framework backed by proprietary intellectual property and offers custom development services designed for collaboration with partners.

In addition to these innovative enzymes, Fapon will address the rising global need for early Alzheimer's diagnosis. The company will unveil a comprehensive suite of raw materials and blood-based reagents targeting essential biomarkers associated with Alzheimer's Disease. This offering, created under strict ISO 13485 standards, empowers IVD manufacturers by streamlining the process of transitioning from initial concept to clinical application.

A Comprehensive Diagnostic Portfolio

Fapon's commitment to providing an extensive portfolio is further emphasized through its Shine i-Series CLIA analyzers. Attendees will be able to engage with live demonstrations of the Shine i1000 and Shine i3000 analyzers, which are engineered to accommodate a range of throughput levels and support over 70 in-house reagents. Alongside instrument showcases, the company will feature essential raw materials including antibodies for small-molecule sandwich assays – notable examples being Vitamin D (25-OH VD), Estradiol (E2), and Thyroxine (FT4/T4). Moreover, the introduction of mouse-free IgG blockers serves as a preferred choice for facilities seeking animal-origin-free products.

These innovations reflect Fapon's dedication to offering validated and high-performance components, which simplify assay development and contribute to improved diagnostic accuracy.

Commitment to North America

Fapon's tagline, “In America, For America,” underlines its relentless focus on serving the North American market efficiently. The company has developed a robust operational presence within the United States, integrating research, development, and production facilities domestically. This strategy is designed to ensure rapid technical support and strengthen the supply chain resilience for local partners. Fapon's infrastructure is supported by a meticulous quality management system, upholding certifications such as ISO 13485, ISO 9001, ISO 14001, and ISO 45001 – vital for meeting the rigorous standards expected by US laboratories and IVD manufacturers.

About Fapon

Fapon stands as a leader in the life sciences field, pushing the boundaries of the diagnostics and therapeutics landscape with its novel AI-driven models that incorporate both dry and wet experimental methodologies. This innovative framework accelerates the discovery and translation of biomarkers and targets, fostering significant advancements in precision medicine. Through an integrated business model, Fapon provides AI-enhanced discovery solutions, comprehensive diagnostic services, and innovative therapeutic options that span the entirety of health management.

To stay updated on their latest developments, follow Fapon on LinkedIn or explore their website at https://us.faponbiotech.com.